TCT

This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures. 

Videos | Antiplatelet and Anticoagulation Therapies | October 17, 2019
VIDEO: New PLATINUM Diversity Data Shows Early DAPT Cessation OK in Minorities With New Generation Stent

Roxana Mehran, M.D., FACC, FACP,...
read more
Videos | Hemodynamic Support Devices | October 16, 2019
VIDEO: Justification for Hemodynamic Support in Complex PCI

...
read more
Videos | Structural Heart | October 16, 2019
VIDEO: Highlighting Women Involved With Structural Heart Interventions

Vivian Ng, M.D.,...
read more
Supraflex Drug-Eluting Stent Superior to Xience in Two-Year Target Vessel Failure
News | Stents Drug Eluting | October 11, 2019
Supraflex Drug-Eluting Stent Superior to Xience in Two-Year Target Vessel Failure

October 11, 2019 — The ultra-thin Supraflex drug-...
read more
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
VIDEO: Early Discontinuation of DAPT in High Bleeding Risk Patients With the Synergy Stent

Ajay J. Kirtane, M.D., associate...
read more
An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no statistically significant mortality increase. This was one of the first major reviews of trial data for patients who were treated with a paclitaxel coated device used in peripheral vessels following a meta analysis study of paclitaxel device trials published in December 2018 that showed a mortality safety signal. This was a major discussion during the FDA townhall meeting at the #TCT2019.
News | Drug-Eluting Balloons | October 10, 2019
LEVANT Trial Data Shows Safety of Drug-Coated Balloon Shown

October 10, 2019 — An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no...
read more
BackBeat CNT is the flagship therapy of Orchestra BioMed Inc. It is a bioelectronic treatment that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS).

The BackBeat CNT system is a bioelectronic treatment that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS). 

News | Hypertension | October 10, 2019
MODERATO II Study: Cardiac Neuromodulation Significantly Reduces Systolic Blood Pressure

October 10. 2019 — Late-breaking results from its MODERATO II double-blind, randomized study of BackBeat Cardiac...
read more
Videos | Antiplatelet and Anticoagulation Therapies | October 10, 2019
VIDEO: TWILIGHT Trial Shows Benefit to Ticagrelor Monotherapy After Stent Implantation

Roxana Mehran, M.D.,...
read more
TCT 2019 Late-breaking Presentations in the main arena. The top interventional cardiology studies of 2019. #TCT #TCT19 #TCT2019
Feature | TCT | October 11, 2019
TCT 2019 Late-breaking Presentations

October 10, 2019 — Here are the Cardiovascular Research Foundation (CRF) 12 late-breaking trials and 16 late-...
read more
Videos | Heart Valve Technology | October 09, 2019
VIDEO: The Expansion of TAVR Following the FDA Clearing its Use in All Patients

Torsten...
read more
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
VIDEO: Overview of Short DAPT in High-risk Bleeding Patients Who Receive Stents

American Heart Association President ...
read more
Videos | TCT | October 04, 2019
VIDEO: SCAI Prospective on Key Takeaways at TCT 2019

Chandan...
read more
A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography. Study Finds Sustained Benefit for TAVR vs. SAVR at One Year. #TCT2019 #TCT19

A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography.

News | Heart Valve Technology | October 04, 2019
Study Finds Sustained Benefit for TAVR vs. SAVR at One Year

October 4, 2019 – A new analysis of the PARTNER 3 Trial data found a modest, but significant, improvement in one-...
read more
The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019
Transcatheter Mitral Valve Replacement is Cost-Effective in Heart Failure Patients

October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve...
read more
RenalGuard Therapy was found to be superior to the POSEIDON method in preventing contrast-induced acute kidney injury (CI-AKI) for patients with kidney disease who undergo interventional cath lab procedures. Results of the 700 patient, randomized, investigator-driven REMEDIAL III Trial presented at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. #TCT19 #TCT2019
News | October 04, 2019
Contrast-Induced Kidney Injury Prevented With RenalGuard in REMEDIAL III Trial

October 4, 2019 – RenalGuard Therapy was found to be superior to the POSEIDON method in preventing contrast-induced...
read more
© Copyright Scranton Gillette Communications. All Rights Reserved.
Overlay Init